To Study the Efficacy of Intravenous Neostigmine in Resolution of Acute GI Paralysis in Critically Ill Cirrhotics-Prospective Observational Study - NI

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Critically ill cirrhosis patient admitted in liver ICU with new onset acute GI tract paralysis and develop feed intolerance.
•2.Patients with new onset lower GI tract paralysis with clinical presentation of feed intolerance defined as GRV more than 500ml, abdominal distension, bowel distension on abdominal imaging, and absence of bowel sounds.

•1.Recent GI bleed
•2.Bronchoconstriction
•3.Bradycardia
•4.Current or past history of surgical abdomen, including mechanical obstruction, mesenteric ischemia, perforation or requiring abdominal surgery.
•5.Prior comorbid illnesses like advanced cardiopulmonary disease, prior episodes of arrhythmia, structural heart diseases, traumatic brain injury, cerebrovascular accidents, raised intracranial pressures, history of myasthenia gravis.
•6.Endocrinological illnesses like uncontrolled hypothyroidism, hypoparathyroidism
•7.Connective tissue disorders including systemic sclerosis, dermatomyositis or polymyositis, systemic lupus erythematosus,amyloidosis.
•8.Pregnant females
•9.Refusal to give consent.

发起方